Clinical trial
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
NCT06794073 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- January 31, 2026
- Completion date
- August 31, 2027
- Enrollment
- 17 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.